Pharmacological treatment of benign prostatic hyperplasia, current options and future perspectives

Scandinavian Journal of Urology and Nephrology, Supplement

Volumn 30, Issue 180, 1996, Pages 48-55

  Hansen, Bo Jesper ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA (2 METHYLALLYL) 19 NORTESTOSTERONE; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; ANTIESTROGEN; BICALUTAMIDE; BUSERELIN; CIBA 31458 BA; CYPROTERONE ACETATE; DOXAZOSIN; FINASTERIDE; FLUTAMIDE; GESTAGEN; GONADORELIN; LEUPRORELIN; MEGESTROL; NAFARELIN; NORETHISTERONE ACETATE; PHENOXYBENZAMINE; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; TESTOLACTONE; UNCLASSIFIED DRUG;

HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW;

EID: 0030338705     PISSN: 03008886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Abrams P & Feneley RCL. The significance of the symptoms associated with bladder outflow obstruction. Urol Int 1978;33:171-4.
2. Abrams P & Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979a;51:129-34.
3. Abrams PH, Farrar Dj, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979b; 121:640-2.
4. Abrams P. New words for old: Lower urinary tract symptoms for "prostatism". Avoids spurious suggestion of diagnostic accuracy. BMJ 1994;308:929-30.
5. Abrams P, Schulman CC, Vaage S. The efficacy and satety of 0.4 mg tamsulosin once daily in symptomatic BPH. J Urol 1995;153 suppl:274A (abstract 183).
6. Andersen JT, Nordling J, Walter S. Prostatism-I. The correlation between symptoms, cystometric and urodynamic findings. Scand J Urol Nephrol 1979;13:229-36.
7. Andersen JT. Prostatism: Clinical, radiological and urodynamic aspects (thesis). Neurourol Urodyn 1982;1:241-93.
8. Andersson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993;45:253-308.
9. Andersson KE. Personal communication. 3rd International Consultation on Benign Prostatic Hyperplasia. WHO, Monaco, June 1995.
10. Ball AJ, Feneley RCL, Abrams PH. The natural history of untrated "prostatism". Br J Urol 1981;53:613-6.
11. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990a;17:495-506.
12. Barry MJ. Medical outcomes research and benign prostatic hyperplasia. The Prostate Suppl 1990b;3:61-74.
13. Barry M, Fowler F, O'Leary M, Bruskewitch R, Holtgrewe HL, Mebust WK, Cockett ATK and the measurement committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992a;148:1549-57.